|
1
|
Madathil KC, Greenstein JS, Juang KA,
Neyens DM and Gramopadhye AK: An investigation of the informational
needs of ovarian cancer patients and their supporters. In:
Proceedings of the Human Factors and Ergonomics Society Annual
Meeting. SAGE Journals. 57:748–752. 2013. View Article : Google Scholar
|
|
2
|
Network CGAR; Cancer Genome Atlas Research
Network: Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khaider NG, Lane D, Matte I, Rancourt C
and Piché A: Targeted ovarian cancer treatment: The TRAILs of
resistance. Am J Cancer Res. 2:75–92. 2012.
|
|
6
|
Liu X, Tang WH, Zhao XM and Chen L: A
network approach to predict pathogenic genes for Fusarium
graminearum. PLoS One. 5:e130212010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Göhre V and Robatzek S: Breaking the
barriers: Microbial effector molecules subvert plant immunity. Annu
Rev Phytopathol. 46:189–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ein-Dor L, Kela I, Getz G, Givol D and
Domany E: Outcome signature genes in breast cancer: Is there a
unique set? Bioinformatics. 21:171–178. 2005. View Article : Google Scholar
|
|
9
|
Zhang L, Li S, Hao C, Hong G, Zou J, Zhang
Y, Li P and Guo Z: Extracting a few functionally reproducible
biomarkers to build robust subnetwork-based classifiers for the
diagnosis of cancer. Gene. 526:232–238. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rodríguez-Paredes M and Esteller M: Cancer
epigenetics reaches mainstream oncology. Nat Med. 17:330–339. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ballestar E and Esteller M: Epigenetic
gene regulation in cancer. Adv Genet. 61:247–267. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu
G, Zhao R, Huang H, Wang X, Qiao Y, et al: MiR-152 and miR-185
co-contribute to ovarian cancer cells cisplatin sensitivity by
targeting DNMT1 directly: A novel epigenetic therapy independent of
decitabine. Oncogene. 33:378–386. 2014. View Article : Google Scholar
|
|
13
|
Stephan L and Momparler R: Combination
chemotherapy of cancer using the inhibitor of DNA methylation
5-aza-2′-deoxy-cytidine (decitabine). J Cancer Res Ther. 3:56–65.
2015. View Article : Google Scholar
|
|
14
|
Chen MY, Liao WS, Lu Z, Bornmann WG,
Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA and Bast RC
Jr: Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit
growth of ovarian cancer cell lines and xenografts while inducing
expression of imprinted tumor suppressor genes, apoptosis, G2/M
arrest, and autophagy. Cancer. 117:4424–4438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matsumura N, Huang Z, Mori S, Baba T,
Fujii S, Konishi I, Iversen ES, Berchuck A and Murphy SK:
Epigenetic suppression of the TGF-beta pathway revealed by
transcriptome profiling in ovarian cancer. Genome Res. 21:74–82.
2011. View Article : Google Scholar :
|
|
16
|
Li J and Tibshirani R: Finding consistent
patterns: A nonparametric approach for identifying differential
expression in RNA-Seq data. Stat Methods Med Res. 22:519–536. 2013.
View Article : Google Scholar
|
|
17
|
Amberger JS, Bocchini CA, Schiettecatte F,
Scott AF and Hamosh A: OMIM org: Online Mendelian Inheritance in
Man (OMIM®), an online catalog of human genes and genetic
disorders. Nucleic Acids Res. 43:D789–D798. 2015. View Article : Google Scholar
|
|
18
|
Franceschini A, Szklarczyk D, Frankild S,
Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, Von Mering
C, et al: STRING v9.1: Protein-protein interaction networks, with
increased coverage and integration. Nucleic Acids Res.
41:D808–D815. 2013. View Article : Google Scholar :
|
|
19
|
Benesty J, Chen J, Huang Y and Cohen I:
Pearson correlation coefficient. Noise Reduction in Speech
Processing. Springer; pp. 1–4. 2009, View Article : Google Scholar
|
|
20
|
Haythornthwaite C: Social network
analysis: An approach and technique for the study of information
exchange. Libr Inf Sci Res. 18:323–342. 1996. View Article : Google Scholar
|
|
21
|
Barthelemy M: Betweenness centrality in
large complex networks. Eur Phys J b Cond Matter Complex Syst.
38:163–168. 2004. View Article : Google Scholar
|
|
22
|
Wasserman S: Social network analysis:
Methods and Applications. Cambridge University Press; 1994,
http://dx.doi.org/10.1017/Cbo9780511815478.
View Article : Google Scholar
|
|
23
|
Fekete SP, Kaufmann M, Kröller A and
Lehmann K: A new approach for boundary recognition in geometric
sensor networks. Proc. 17th Canadian Conference on Computational
Geometry; pp. 82–85. 2005
|
|
24
|
Huang W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar
|
|
25
|
Wang X and Simon R: Microarray-based
cancer prediction using single genes. BMC Bioinformatics.
12:3912011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vogt PK, Hart JR, Gymnopoulos M, Jiang H,
Kang S, Bader AG, Zhao L and Denley A: Phosphatidylinositol
3-kinase: The oncoprotein. Phosphoinositide 3-kinase in Health and
Disease. Springer; pp. 79–104. 2010, View Article : Google Scholar
|
|
27
|
Herrero-Gonzalez S and Di Cristofano A:
New routes to old places: PIK3R1 and PIK3R2 join PIK3CA and PTEN as
endometrial cancer genes. Cancer Discov. 1:106–107. 2011.
View Article : Google Scholar
|
|
28
|
Fayard E, Xue G, Parcellier A, Bozulic L
and Hemmings BA: Protein kinase B (PKB/Akt), a key mediator of the
Pi3k signaling pathway. Phosphoinositide 3-kinase in Health and
Disease. Springer; pp. 31–56. 2011
|
|
29
|
Wu R, Hu TC, Rehemtulla A, Fearon ER and
Cho KR: Preclinical testing of PI3K/AKT/mTOR signaling inhibitors
in a mouse model of ovarian endometrioid adenocarcinoma. Clin
Cancer Res. 17:7359–7372. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
De Graeff P, Crijns AP, Ten Hoor KA, Klip
HG, Hollema H, Oien K, Bartlett JM, Wisman GB, de Bock GH, de Vries
EG, et al: The ErbB signalling pathway: Protein expression and
prognostic value in epithelial ovarian cancer. Br J Cancer.
99:341–349. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thiele CJ, Li Z and Mckee AE: On Trk - the
Trkb signal transduction pathway is an increasingly important
target in cancer biology. Clin Cancer Res. 15:5962–5967. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cheung LW, Hennessy BT, Li J, Yu S, Myers
AP, Djordjevic B, Lu Y, Stemke-Hale K, Dyer MD, Zhang F, et al:
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer
elucidates a novel mechanism for regulation of PTEN protein
stability. Cancer Discov. 1:170–185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Egloff AM, Vella LA and Finn OJ: Cyclin B1
and other cyclins as tumor antigens in immunosurveillance and
immunotherapy of cancer. Cancer Res. 66:6–9. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ding K, Li W, Zou Z, Zou X and Wang C:
CCNB1 is a prognostic biomarker for ER+ breast cancer. Med
Hypotheses. 83:359–364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liao W, Lin JX and Leonard WJ:
Interleukin-2 at the crossroads of effector responses, tolerance,
and immunotherapy. Immunity. 38:13–25. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wilke CM, Kryczek I and Zou W:
Antigen-presenting cell (APC) subsets in ovarian cancer. Int Rev
Immunol. 30:120–126. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Duraiswamy J, Freeman GJ and Coukos G:
Therapeutic PD-1 pathway blockade augments with other modalities of
immunotherapy T-cell function to prevent immune decline in ovarian
cancer. Cancer Res. 73:6900–6912. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang X, Xiao D, Wang Z, Zou Y, Huang L,
Lin W, Deng Q, Pan H, Zhou J, Liang C, et al: MicroRNA-26a/b
regulate DNA replication licensing, tumorigenesis, and prognosis by
targeting CDC6 in lung cancer. Mol Cancer Res. 12:1535–1546. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Blow JJ and Gillespie PJ: Replication
licensing and cancer - a fatal entanglement? Nat Rev Cancer.
8:799–806. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Booher K, Lin DW, Borrego SL and Kaiser P:
Downregulation of Cdc6 and pre-replication complexes in response to
methionine stress in breast cancer cells. Cell Cycle. 11:4414–4423.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Deng Y, Jiang L, Wang Y, Xi Q, Zhong J,
Liu J, Yang S, Liu R, Wang J, Huang M, et al: High expression of
CDC6 is associated with accelerated cell proliferation and poor
prognosis of epithelial ovarian cancer. Pathol Res Pract. Sep
18–2015.(Epub ahead of print). pii: S0344-0338(15)30014-5.
View Article : Google Scholar
|
|
42
|
Creighton CJ, Hernandez-Herrera A,
Jacobsen A, Levine DA, Mankoo P, Schultz N, Du Y, Zhang Y, Larsson
E, Sheridan R, et al Cancer Genome Atlas Research Network:
Integrated analyses of microRNAs demonstrate their widespread
influence on gene expression in high-grade serous ovarian
carcinoma. PLoS One. 7:e345462012. View Article : Google Scholar : PubMed/NCBI
|
